feedback

Course Directors

Leonard Calabrese
Leonard Calabrese, DO

Department of Rheumatic & Immunologic Diseases
Cleveland Clinic
Cleveland, OH

M. Elaine Husni
M. Elaine Husni, MD, MPH

Assistant Professor
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Director, Clinical Outcomes Research
Director, Arthritis and Musculoskeletal Treatment Center
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Faculty

Carmen Gota, MD

Center for Vasculitis Care
Research Department of Rheumatologic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Bochra Jandali, MD

University Hospitals
Cleveland, OH

Jonathan Kay, MD

Director, Clinical Trials
Rheumatology Unit
Massachusetts General Hospital
Associate Clinical Professor of Medicine
Harvard Medical School
Boston, MA

Elizabeth Kirchner, MSN, CNP

Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Gregg J. Silverman, MD

Professor of Medicine
Director, Laboratory of B-Cell Immunology
Division of Rheumatology, Allergy, and Immunology
University of California San Diego School of Medicine
La Jolla, CA

Accredited by

Cleveland Clinic Center for Continuing Education

Course Description

Learning Objectives
1. Summarize the current knowledge of the biology and pathology of autoimmune and inflammatory disease.
2. Describe the impact of bioengineering and biosimilars on biologic therapy efficacy, toxicity, and changing patterns of use.
3. Critically appraise the "treat to target" philosophy and describe strategies to incorporate it into clinical practice.
4. Summarize data on vaccine efficacy and safety and develop strategies to incorporate vaccines into clinical practice with the goal of enhancing the safety of biologic therapies.
5. Critically assess clinical data on biologic use in the related specialties of dermatology, oncology, neurology, and gastroenterology; synthesize their insights on shared mechanisms and new pathways for different diseases to potential implications for rheumatology.
6. Describe the efficacy and safety of biologic therapies and emerging new agents for systemic lupus erythematosus, Sjögren's syndrome, osteoporosis, vasculitis, and other disorders.
7. Develop strategies for improving safety and increasing adherence when using biologics by appraising best practices of experts and engaging in interactive case discussions.

Activity Details

Credit Types:CME
Credit Amount:1.50 Credits
Release Date:2015-Oct-29
Expiration Date:2017-Oct-29
Estimated Time for Completion:1.5 hours
Registration Required:No
Cost:Free

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.